于凝,惠永明,马超,熊永红,仲崇星

• 1:北京丰台医院心内科CCU病房

摘要(Abstract)：

目的观察非ST段抬高型急性冠状动脉综合征患者经皮冠状动脉介入治疗(PCI)术后应用不同剂量的氯吡格雷疗效和安全性。方法共入选急性非ST段抬高型冠状动脉综合征行PCI术的患者506例,计算机简单随机法分为标准组、强化组。标准组入院后给予氯吡格雷300mg顿服,后予75mg/d维持;强化组入院后给予300mg顿服,后予150mg/d口服至PCI术后5d,后75mg/d维持。所有患者均于入院、顿服氯吡格雷300mg后24h、术前及术后5d行ADP诱导的血小板聚集率(PA)检查。于入院及术后5d行血常规检查,观察血小板变化,并随访术后30d主要心血管事件和出血事件的发生情况。结果强化组术前及术后5d的PA明显下降,强化组术前及术后5d的PA(%)较标准组明显减低,差异具有统计学意义(t=18.3929,P<0.05;t=13.1384,P<0.005)。强化组与标准组比较30d主要心血管事件有减低趋势,但未见有统计学意义。两组TIMI出血事件未见有明显差异。结论强化抗血小板治疗可以明显抑制血小板聚集率,同时出血风险未见明显增加,是安全可行的。

关键词(KeyWords)： 氯吡格雷;血管成形术,经腔,经皮冠状动脉;血小板聚集;急性冠状动脉综合征

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 于凝,惠永明,马超,熊永红,仲崇星

参考文献(References)：

• [1]Kaiser C,Brunner-La Rocca HP,Buser PT,et al.Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting:randomised Basel Stent Koseten Effektivitats Trial(BASKET).Lancent,2005,366:921-929.
• [2]Serebruany VL,Steinhubl SR,berger PB,et al.Variability in platelet responsiveness to clopidogrel among544individuals.J Am Coil Cardiol,2005,45:246-251.
• [3]Wenaweser P,Drffler-Melly J,Imboden K,et al.Stent thrombosis is associated with an impaired response to antiplatelet therapy.J Am Coll Cardiol,2005,45:1748-1752.
• [4]Rao Ak,Pratt C,Berke A,et al.Thrombolysis in Myocardial(TIMI)Trial-phase I:hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.J Am Coll Cardiol,1988,11:1-11.
• [5]CAPRIE Steering Committee.A randomized,blinded,trial of clopidogrel versus aspirin in patients at risk of ischemic events(CAPRIE).Lancet,1996,348:1329-1339.
• [6]Gurbel PA,Tantry US.Aspirin and clopidogrel resistance:consideration and management.J Interv Cardiol,2006,19:439-448.
• [7]Yusuf S,Zhao F,Mehta SR,et al.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.N Engl J Med,2001,345:494-502.
• [8]Steinhubl SR,Berger PB,Mann JT3rd,et al.Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:a randomized controlled trial.JAMA,2002,288:2411-2420.
• [9]Gorog P,Ridler CD,Rees GM,et al.Evidence against hypercoagulability in coronary artery disease.Thromb Res,1995,79:377-385.
• [10]von Beckerath N,Kastrati A,Wieczorek A,et al.A double blind randomized comparison between two different clopidogrel maintenance doses after percutaneous coronary intervention(ISAR-CHOICE2Trial).Eur Heart J,2006,27:5039.
• [11]Angiolillo DJ,Shoemaker SB,Desai B,et al.Randomized comparisonof a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease:results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus(OPTIMUS)study.Circulation,2007,115:708-716.
• [12]Bonello L,Camoin-Jau L,Arques S,et al.Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance:a multicenter randomized prospective study.J Am Coll Cardiol,2008,51:1404-1411.
• [13]Matetzky S,Shenkman B,Guetta V,et al.Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.Circulation,2004,109:3171-3175.
• [14]Gurbel PA,Bliden KP,Hiatt BL,et al.Clopidogrel for coronary stenting:response variability,drug resistance,and the effect of pretreatment platelet reactivity.Circulation,2003,107:2908-2913.
• [15]李靖,王乐丰,徐琳,等.高维持剂量氯吡格雷对急性心肌梗死患者急诊介入术后血小板聚集率和高敏C反应蛋白水平的影响.中国介入心脏病学杂志,2010,18:16-20.